ENGN

enGene TherapeuticsB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-20

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$4.50

+140.6% vs current

Most likely

Base case

45%

Probability

Target price

$1.80

-3.7% vs current

B-

Bear case

30%

Probability

Target price

$0.70

-62.6% vs current

AI sentiment snapshot

Latest data as of 2026-06-12

AI commentary

Sentiment remains cautious and event-driven. The May 7 company update reset the story around durability, and subsequent trusted coverage linked the sell-off to analyst downgrades rather than to a resolved operating issue. The June 11 anchor price of $1.64 shows that most of the repricing has held, and the June 10 8-K added no operating rebuttal because it only covered annual-meeting votes. No usable social-context packet was provided, so conviction should continue to rest on filings and company releases, not narrative momentum.

RankAlpha Sentiment Codex - 2026-06-12

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-30catalystNear-term information vacuum keeps post-data sentiment fragileHigh impact

The June 10, 2026 8-K only reported annual-meeting voting results and did not add an operating update, leaving the stock without a fresh corrective catalyst after the May LEGEND durability disappointment; that raises the odds of continued drift until a substantive clinical or regulatory communication arrives [#8-K-2026-06-10].

2026-09-30event2H 2026 LEGEND 12-month durability update is still the key clinical resetHigh impact

Management said on March 9 that 12-month complete-response data from the LEGEND pivotal cohort are expected in 2H 2026, but the May 7 update showed only 13 of 22 evaluated patients remained in complete response at 12 months and the Kaplan-Meier estimate of 12-month duration of response was 25%, keeping the next durability readout as the main swing factor for credibility and valuation [#SEC-8K-2026-03-09] [#PR-EARNINGS-2026-05-07].

2026-12-31catalyst2H 2026 BLA path and FDA dialogue will determine whether the platform can re-rateHigh impact

The March 9 company update said a BLA submission for detalimogene is planned for 2H 2026 and cash plus marketable securities of $312.5 million are expected to fund operations into 2H 2028; the May 7 release added that required manufacturing validation batches were completed and a statistical analysis plan was submitted to FDA, but further FDA engagement is still needed before investors can underwrite the filing path with confidence [#SEC-8K-2026-03-09] [#PR-EARNINGS-2026-05-07].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-12 • Updated nightlySource: Internal modelMethodology